title: Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
authors.forename: Steven M
authors.initials: SM
authors.lastname: Sorscher
authors.forename: Albert Craig
authors.initials: AC
authors.lastname: Lockhart
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D011499:Protein Processing, Post-Translational; D053245:RANK Ligand / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D000077211:Zoledronic Acid; D018631:ras Proteins / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004164:Diphosphonates; D007093:Imidazoles; D053245:RANK Ligand; D000069448:Denosumab; D000077211:Zoledronic Acid; D018631:ras Proteins